Rigel Pharmaceuticals, Inc.RIGLNASDAQ
Loading
Net Income Growth AcceleratingAccelerating
Percentile Rank97
3Y CAGR+100.1%
Year-over-Year Change
Year-over-year net income growth rate
3Y CAGR
+100.1%/yr
vs +31.4%/yr prior
Acceleration
+68.8pp
Accelerating
Percentile
P97
Near historical high
vs 3Y Ago
8x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 860.81% |
| Q3 2025 | -53.20% |
| Q2 2025 | 420.82% |
| Q1 2025 | -20.19% |
| Q4 2024 | 15.46% |
| Q3 2024 | 1305.92% |
| Q2 2024 | 87.51% |
| Q1 2024 | -1219.00% |
| Q4 2023 | 112.95% |
| Q3 2023 | 13.76% |
| Q2 2023 | 51.24% |
| Q1 2023 | -1066.17% |
| Q4 2022 | 107.36% |
| Q3 2022 | -41.10% |
| Q2 2022 | 50.84% |
| Q1 2022 | -21.22% |
| Q4 2021 | -8.06% |
| Q3 2021 | -51.60% |
| Q2 2021 | -134.99% |
| Q1 2021 | 305.33% |
| Q4 2020 | -35.72% |
| Q3 2020 | 19.36% |
| Q2 2020 | -182.74% |
| Q1 2020 | 223.51% |
| Q4 2019 | -49.70% |
| Q3 2019 | 44.24% |
| Q2 2019 | -17.09% |
| Q1 2019 | -645.17% |
| Q4 2018 | 113.58% |
| Q3 2018 | 7.01% |
| Q2 2018 | -4.81% |
| Q1 2018 | 5.74% |
| Q4 2017 | -46.49% |
| Q3 2017 | 7.77% |
| Q2 2017 | -25.03% |
| Q1 2017 | 1.77% |
| Q4 2016 | 31.11% |
| Q3 2016 | -67.21% |
| Q2 2016 | 22.51% |
| Q1 2016 | -37.65% |